A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Korean and Taiwanese Subjects With Chronic Genotype 1 HCV Infection
Latest Information Update: 07 Feb 2019
Price :
$35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 04 Dec 2018 Results presented in the Gilead Sciences media release.
- 04 Dec 2018 According to a Gilead Sciences media release, the National Medical Products Administration(NMPA) has approved Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) in China for the treatment of chronic hepatitis C virus (HCV) genotype 1-6 infection in adults and adolescents aged 12 to 18 years, based on the results of this trial.
- 24 Oct 2017 Results assessing the safety and efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV Infected Chinese Population (n=206) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases